Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Vapers have headed to stores to see if they can get their hands on the pods before they're pulled from shelves.

Juul hoarders stock up on e-cigarettes after FDA announces ban

Juul must stop distributing and selling its e-cigarettes or face enforcement action, the agency says.

FDA Orders Juul to Stop Selling in the US

The axe has fallen for e-cigarette maker Juul. The FDA ordered the company to stop selling and distributing its ubiquitous vaping devices in the U.S. Thursday, a dramatic end for a company that dominated the e-cigarette market and was valued at $38 billion at the top of its game.

FDA orders Juul to stop selling its vaping products in the U.S.

Action is part of effort by Food and Drug Administration to bring scientific scrutiny to multibillion-dollar vaping industry

E-cigarettes: FDA bans market-leading Juul in blow to US tobacco industry

Juul Labs is in focus on Thursday after the Food and Drug Administration barred it from selling its e-cigarettes in the United States. Former FDA commissioner reacts to the news on CNBC Yet, e-cigarettes from rivals RJ Reynolds, NJOY, and Logic remain authorised for sale in the U.S. Explaining why on CNBC's “Squawk Box”, former […] The post Juul e-cigarette ban: here's what former FDA boss Dr Gottlieb has to say appeared first on Invezz.

Juul e-cigarette ban: here's what former FDA boss Dr Gottlieb has to say

The U.S. Food and Drug Administration on Thursday banned Juul Labs Inc. from marketing its vape products in the U.S. and ordered the company to remove all existing products from the market.

FDA bans Juul vape products and orders all current ones to be removed from market

A vaping company has been blocked from selling e-cigarettes in the US.

US vaping company ordered to pull electronic cigarettes from shelves

Juul rebranded three times, sold assets to Japan Tobacco, and attracted nontraditional investors. Now, its products have been banned in the US.

The rise and fall of e-cig startup Juul in the US, from Silicon Valley darling to a ban by the FDA

The feds officially banned the sale of Juul e-cigarettes within the United States on Thursday following years of mounting pressure to address the harmful effects of a youth vaping trend. The US Food and Drug Administration said its ban applied to the Juul device and “all of their products currently marketed” in the US, including.

FDA officially bans sale of Juul e-cigarettes in the US

The U.S. Food and Drug Administration said Thursday it has issued marketing denial orders to Juul Labs Inc. for all of its products that are currently marketed in the U.S., and ordered the company to remove all or risk enforcement action. The products in question comprise the Juul device and four types of pods; Virginia tobacco flavored pods at nicotine concentrations of 5.0% and 3.0% and menthol flavored pods at nicotine concentrations of 5.0% and 3.0%.

FDA denies marketing authorization to Juul products and orders all existing ones to be removed from U.S. market

Juul had submitted an application to the FDA almost two years ago asking the agency to allow its menthol and tobacco-flavored products to remain on the market.

FDA Bans Juul E-Cigarettes From U.S. Market

(Reuters) -The Food and Drug Administration on Thursday blocked e-cigarette maker Juul Labs Inc from selling its nicotine products in the United States, potentially dealing a fatal blow to the once high-flying San Francisco company.

U.S. FDA halts sales of Juul e-cigarettes

The Food and Drug Administration rejected Juul's application to sell its e-cigarettes in the U.S.

FDA bans Juul e-cigarettes as government pursues broader crackdown on nicotine products

Altria shares fell 9.2% after reports of an upcoming FDA ban on Juul products, and now have an 8.9x P/E and an 8.7% Dividend Yield. We believe investors over-reacted. Any FDA ban may not be final, and some announced bans have already been overturned or stayed.

Altria: No Reason To Panic On Rumored FDA Ban On Juul

The ban is in response to growing concern flavoured nicotine products are increasing underage tobacco use

FDA poised to ban Juul e-cigarettes from sale in US

It's almost Shakespearean. Juul, the e-cigarette company that took the U.S. by storm five years ago — and which was valued at its peak at $38 billion — is about to get kicked out of the country, according to the WSJ.

Juul, the high-flying e-cig maker started at Stanford, watches its U.S. market share get vaporized

U.S. health officials will likely reject Juul's products. However, Juul contributes next to nothing to Altria's bottom line.

Altria: Juul No Jewel

VANCOUVER, BC , June 22, 2022 /PRNewswire/ - PODA HOLDINGS, INC. ("PODA" or the "Company") (CSE: PODA) (‎FSE: 99L) (OTC: PODAF) is pleased to announce that, further to its news release dated May 13, 2022 in respect of the proposed sale of all or substantially all of the Company's assets to Altria Client Services LLC ("Altria"), a subsidiary of Altria Group, Inc. (NYSE:MO) (the "Transaction"), the Company's Shareholders have unanimously approved all of the special resolutions required for completion of the Transaction and the Distribution (as described below) at PODA's special meeting of Shareholders (the "Meeting"), which was held on June 22, 2022.

PODA Announces Results of Special Meeting of Shareholders

Kohl's

The market finished mixed in volatile trading.

Surprisingly Bad News Hit These 2 Stocks Hard Wednesday

A regulatory ruling could dent the tobacco titan's fortunes.

Why Altria Stock Plunged Today

The Wall Street Journal reported the FDA will refuse to allow the vape products of Juul Labs to stay on the U.S. market, which would be bad news for investor Altria.

The FDA's One-Two Punch Takes Down Tobacco Stock

Altria's fall has been drastic, losing about 30% in a matter of weeks. As painful as the current situation is, great returns are made under such opportunities.

Altria: Heroes Are Made When The Chips Are Down

A Wall Street Journal report just spelled trouble for Altria Group Inc (NYSE:MO), whose shares were last seen down 9.4% to trade at $41.42, earlier making its way onto the short sale restricted (SSR) list.

Altria Stock Sinks Amid Reports of Juul Ban

A report that the Food and Drug Administration might order Juul to pull its products from store shelves has sent shares of Altria plunging. The cigarette company owns a 35% stake in Juul.

Juul vape pens could be pulled from US shelves. Altria shares tumble

Altria Inc. shares slid 9% Wednesday, after a report that the Food and Drug Administration is preparing to order Juul Labs Inc., in which Altria owns a large stake, to take its e-cigarettes off the U.S. market.

News for Altria Stock (MO)